Number of Aβ inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels

DNA and Cell Biology

Volumn 20, Issue 11, 2001, Pages 731-736

  Wilcock, Donna M ^a   Melachrino, Jason ^a   Hardy, John ^a   Morgan, David ^a   Gordon, Marcia N ^a   Ugen, Kenneth E ^a   Gottschall, Paul E ^a   Di Carlo, Giovanni ^a   Dickey, Chad ^a   Boyett, Kristal W ^a   Jantzen, Paul T ^b   Connor, Karen E ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CD45 ANTIGEN; CONGO RED; MEMBRANE PROTEIN; PRESENILIN 1; AMYLOID BETA PROTEIN[1-42]; ANTIBODY; UNCLASSIFIED DRUG; VACCINE;

ALZHEIMER DISEASE; ANIMAL; ANTIBODY PRODUCTION; ARTICLE; GENETICS; IMMUNOLOGY; METABOLISM; MICROGLIA; MOUSE; NEUROFIBRILLARY TANGLE; TRANSGENIC MOUSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN EXPRESSION; CELL ACTIVATION; CLEARANCE; CONTROLLED STUDY; CORRELATION FUNCTION; GENOTYPE; HISTOPATHOLOGY; INOCULATION; NONHUMAN; PRIORITY JOURNAL; STAINING; STATISTICS; VACCINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODY FORMATION; ANTIGENS, CD45; CONGO RED; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; MICROGLIA; NEUROFIBRILLARY TANGLES; PRESENILIN-1;

ANIMALIA; MUS MUSCULUS;

EID: 0035544150     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/10445490152717596     Document Type: Article

References (22)

1. Inflammation and Alzheimer’s disease
2. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy
3. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer’s disease
4. Beta-amyloid converts an acute phase injury response to chronic injury responses
5. Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice
6. Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer’s disease-associated β-amyloid 1-42 peptide
7. Increased amyloid-beta 42 (43) in brains of mice expressing mutant presenilin 1
8. Correlation between cognitive deficits and Ab deposits in transgenic APP+PS1 mice
9. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse
10. Exaggerated astrocyte reactivity after nigrostriatal deafferentation in the aged rat
11. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes
12. Behavioural changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: Lack of association with amyloid deposits
13. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice
14. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease
15. Microglial activation Aβ deposit reduction caused by nitric oxide releasing NSAID NCX- 2216, in APP+PS1 mice
16. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases
17. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease
18. Microglial cells internalize aggregates of the Alzheimer’s disease amyloid β-protein via a scavenger receptor
19. Inflammation and Alzheimer’s disease pathogenesis
20. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
21. The molecular pathology of Alzheimer’s disease
22. Immunotherapeutic strategies for prevention and treatment of Alzheimer’s disease